39 related articles for article (PubMed ID: 17614273)
1. Letter to the Editor: The theoretical challenges of routinely using [
Duarte PS
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3824-3825. PubMed ID: 37555903
[No Abstract] [Full Text] [Related]
2. [
Peng L; Liao Y; Zhou R; Zhong Y; Jiang H; Wang J; Fu Y; Xue L; Zhang X; Sun M; Feng G; Meng Z; Peng S; He X; Teng G; Gao X; Zhang H; Tian M
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3723-3734. PubMed ID: 37401938
[TBL] [Abstract][Full Text] [Related]
3. Performance of dedicated breast PET in breast cancer screening: comparison with digital mammography plus digital breast tomosynthesis and ultrasound.
Yuge S; Miyake KK; Ishimori T; Kataoka M; Matsumoto Y; Torii M; Yakami M; Isoda H; Takakura K; Morita S; Takada M; Toi M; Nakamoto Y
Ann Nucl Med; 2023 Sep; 37(9):479-493. PubMed ID: 37280410
[TBL] [Abstract][Full Text] [Related]
4. Extra-articular findings with FDG-PET/CT in rheumatoid arthritis patients: more harm than benefit.
Ulijn E; den Broeder AA; Boers N; Gotthardt M; Bouman CAM; Landewé R; den Broeder N; van Herwaarden N
Rheumatol Adv Pract; 2022; 6(1):rkac014. PubMed ID: 35311064
[TBL] [Abstract][Full Text] [Related]
5. Relationship between Standard Uptake Values of Positron Emission Tomography/Computed Tomography and Salivary Metabolites in Oral Cancer: A Pilot Study.
Ishikawa S; Hiraka T; Kirii K; Sugimoto M; Shimamoto H; Sugano A; Kitabatake K; Toyoguchi Y; Kanoto M; Nemoto K; Soga T; Tomita M; Iino M
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33297326
[No Abstract] [Full Text] [Related]
6. Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy.
Chan HP; Liu WS; Liou WS; Hu C; Chiu YL; Peng NJ
In Vivo; 2020; 34(1):469-478. PubMed ID: 31882515
[No Abstract] [Full Text] [Related]
7. [Systematic errors in clinical studies : A comprehensive survey].
Golder WA
Ophthalmologe; 2017 Mar; 114(3):215-223. PubMed ID: 28236001
[TBL] [Abstract][Full Text] [Related]
8. [Systematic errors in clinical studies : A comprehensive survey].
Golder WA
Z Rheumatol; 2017 Feb; 76(1):71-82. PubMed ID: 28083633
[TBL] [Abstract][Full Text] [Related]
9. Application of whole-body FDG-PET for cancer screening in a cohort of hospital employees.
Hu C; Liu CP; Cheng JS; Chiu YL; Chan HP; Peng NJ
Medicine (Baltimore); 2016 Nov; 95(44):e5131. PubMed ID: 27858845
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of FDG-PET cancer screening in asymptomatic individuals: use of record linkage from the Osaka Cancer Registry.
Sengoku T; Matsumura K; Usami M; Takahashi Y; Nakayama T
Int J Clin Oncol; 2014 Dec; 19(6):989-97. PubMed ID: 24481919
[TBL] [Abstract][Full Text] [Related]
11. What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?
Bhosale P; Balachandran A; Vikram R; Viswanathan C; Macapinlac H; Rohren E; Prativadi R
Int J Mol Imaging; 2013; 2013():476786. PubMed ID: 24455242
[TBL] [Abstract][Full Text] [Related]
12. The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey.
Minamimoto R; Senda M; Jinnouchi S; Terauchi T; Yoshida T; Murano T; Fukuda H; Iinuma T; Uno K; Nishizawa S; Tsukamoto E; Iwata H; Inoue T; Oguchi K; Nakashima R; Inoue T
Ann Nucl Med; 2013 Jan; 27(1):46-57. PubMed ID: 23086544
[TBL] [Abstract][Full Text] [Related]
13. Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images.
Han EJ; H O J; Choi WH; Yoo IR; Chung SK
Br J Radiol; 2010 Nov; 83(995):915-20. PubMed ID: 20965901
[TBL] [Abstract][Full Text] [Related]
14. Incidental fleurodeoxyglucose uptake in the prostate.
Wong WL; Moule RN; Nunan T
Br J Radiol; 2010 Nov; 83(995):902-3. PubMed ID: 20965899
[TBL] [Abstract][Full Text] [Related]
15. Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardised PET cut-off.
Luboldt W; Volker T; Wiedemann B; Zöphel K; Wehrmann U; Koch A; Toussaint T; Abolmaali N; Middendorp M; Aust D; Kotzerke J; Grünwald F; Vogl TJ; Luboldt HJ
Eur Radiol; 2010 Sep; 20(9):2274-85. PubMed ID: 20503051
[TBL] [Abstract][Full Text] [Related]
16. Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: The Nishidai clinic study.
Kojima S; Zhou B; Teramukai S; Hara A; Kosaka N; Matsuo Y; Suzuki H; Torigoe S; Suzuki T; Uno K; Fukushima M
Eur J Cancer; 2007 Aug; 43(12):1842-8. PubMed ID: 17614273
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
[TBL] [Abstract][Full Text] [Related]
18. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.
Minamimoto R; Senda M; Uno K; Jinnouchi S; Iinuma T; Ito K; Okuyama C; Oguchi K; Kawamoto M; Suzuki Y; Tsukamoto E; Terauchi T; Nakashima R; Nishio M; Nishizawa S; Fukuda H; Yoshida T; Inoue T
Ann Nucl Med; 2007 Nov; 21(9):481-98. PubMed ID: 18030580
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report.
Nishizawa S; Kojima S; Teramukai S; Inubushi M; Kodama H; Maeda Y; Okada H; Zhou B; Nagai Y; Fukushima M
J Clin Oncol; 2009 Apr; 27(11):1767-73. PubMed ID: 19255324
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
